Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

Launched by UNIVERSITY OF COLOGNE · May 16, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: Platelet Response to Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura**

This clinical trial is looking at how a treatment called caplacizumab affects the platelet counts in patients with a specific blood condition known as acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab is designed to help normalize platelet counts quickly, often within just a few days. However, the way platelets respond to this treatment can be unpredictable. Some patients might see a rapid increase in their platelet count, followed by a sudden drop. This can confuse doctors and lead them to give more treatment than necessary, which could cause side effects. The trial aims to better understand these patterns of platelet response, identify potential challenges for healthcare providers, and help predict how individual patients will respond to caplacizumab.

To participate in this trial, patients must be at least 18 years old and have a confirmed diagnosis of autoimmune thrombotic thrombocytopenic purpura. They should have received at least one dose of caplacizumab, either through an injection into a vein or under the skin. The study is currently recruiting participants, and it welcomes both men and women. This research is important as it will help doctors provide better care by understanding how different patients respond to caplacizumab treatment, ultimately leading to safer and more effective management of this complex condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of autoimmune thrombotic thrombocytopenic purpura
• • Treatment with at least a single dose of caplacizumab, either i.v. or s.c.
• • Male or female patients older than 18 years of age
• Exclusion Criteria:
• • Hereditary thrombotic thrombocytopenic purpura